Renal artery sympathetic denervation: observations from the UK experience

@inproceedings{Sharp2015RenalAS,
  title={Renal artery sympathetic denervation: observations from the UK experience},
  author={Andrew S. P. Sharp and Justin E. Davies and Melvin D Lobo and Clare Louise Bent and Patrick B Mark and Amy E. Burchell and Simon D R Thackray and Una Martin and W Mckane and Robert T. Gerber and James Richard Wilkinson and Tarek Francis Antonios and Timothy W R Doulton and Tiffany Patterson and Piers C. Clifford and Alistair Lindsay and Graeme Houston and Jonathan S Freedman and Neelan Das and Anna Maria Belli and Mohamad Faris and Trevor J. Cleveland and Angus K. Nightingale and Awais Hameed and Kalaivani Mahadevan and Judith A. Finegold and Adam N. Mather and Terry M Levy and Richard J. D’Souza and Peter L. Riley and Jonathan Moss and Carlo di Mario and Simon Robert Redwood and Andreas Baumbach and Mark J. Caulfield and Indranil Dasgupta},
  booktitle={Clinical Research in Cardiology},
  year={2015}
}
Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response—particularly in those prescribed aldosterone antagonists at the time of RDN. We examined all patients treated with RDN for treatment-resistant hypertension in 18 UK centres. Results from 253 patients treated with five technologies are shown. Pre-procedural mean office BP (OBP… CONTINUE READING